Genetic test could guide use of cancer chemotherapy

by Ellie Cawthera,Imperial College LondonDiscovery ofKRASG12mutation status as potential biomarker of outcome of FTD/TPI treatment in mCRC.a, Dot plot showing the associations

Updated on: December 25,2023

Genetic test could guide use of cancer chemotherapy

by Ellie Cawthera,Imperial College LondonDiscovery ofKRASG12mutation status as potential biomarker of outcome of FTD/TPI treatment in mCRC.a, Dot plot showing the associations

Updated on:December 25,2023

Testing hundreds of therapeutics outside the body to predict their effectiveness against multiple myeloma

by Peter Rüegg,ETH ZurichBone-marrow cells of a multiple myeloma patient. Red cells are healthy monocytes, green and yellow are plasma cells. Credit: Berend Snijder Lab / ETH ZurichMultiple myel

Updated on: February 20,2024

Testing hundreds of therapeutics outside the body to predict their effectiveness against multiple myeloma

by Peter Rüegg,ETH ZurichBone-marrow cells of a multiple myeloma patient. Red cells are healthy monocytes, green and yellow are plasma cells. Credit: Berend Snijder Lab / ETH ZurichMultiple myel

Updated on:February 20,2024

Mounjaro beats Ozempic for weight loss in early trial

by Robin FosterThe diabetes drug Mounjaro prompted more weight loss among overweight and obese adults than Ozempic did in a real-world setting, researchers report.Both Mounjaro (tirzepatide) and Ozemp

Updated on: March 06,2024

Mounjaro beats Ozempic for weight loss in early trial

by Robin FosterThe diabetes drug Mounjaro prompted more weight loss among overweight and obese adults than Ozempic did in a real-world setting, researchers report.Both Mounjaro (tirzepatide) and Ozemp

Updated on:March 06,2024

Novel form of immunotherapy could revolutionize cancer treatment

by Noelle Toumey Reetz,Georgia State UniversityFig. 1: Local RT eliminates late-stage MC38 tumors in Sirpα−/− mice but not WT mice. From: Intratumoral SIRPα-deficient macrophages activate tumor

Updated on: March 25,2024

Novel form of immunotherapy could revolutionize cancer treatment

by Noelle Toumey Reetz,Georgia State UniversityFig. 1: Local RT eliminates late-stage MC38 tumors in Sirpα−/− mice but not WT mice. From: Intratumoral SIRPα-deficient macrophages activate tumor

Updated on:March 25,2024

Researchers find breast cancer protein that could predict chemotherapy sensitivity

by Hunter Medical Research InstituteThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for

Updated on: February 20,2024

Researchers find breast cancer protein that could predict chemotherapy sensitivity

by Hunter Medical Research InstituteThree-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for

Updated on:February 20,2024

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

by Peter Thorley,University of WarwickCredit: CC0 Public DomainA new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast

Updated on: March 14,2024

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

by Peter Thorley,University of WarwickCredit: CC0 Public DomainA new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast

Updated on:March 14,2024

Fourth SARS-CoV-2 vaccination also protects cancer patients

by Johannes Angerer,Medical University of ViennaReceptor-Binding Domain and Angiotensin-Converting Enzyme 2 Interaction Inhibition in Patients With Hematologic Malignant Neoplasm With or Without

Updated on: December 20,2023

Fourth SARS-CoV-2 vaccination also protects cancer patients

by Johannes Angerer,Medical University of ViennaReceptor-Binding Domain and Angiotensin-Converting Enzyme 2 Interaction Inhibition in Patients With Hematologic Malignant Neoplasm With or Without

Updated on:December 20,2023

Predicting DCIS upgrade to invasive cancer at breast surgery with ultrafast imaging

by American Roentgen Ray SocietyA) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip

Updated on: January 28,2024

Predicting DCIS upgrade to invasive cancer at breast surgery with ultrafast imaging

by American Roentgen Ray SocietyA) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip

Updated on:January 28,2024

Long-term study reveals more genetic mutations associated with aggressive prostate cancer

byInstitute of Cancer ResearchXenograft model of prostate cancer. Credit: National Institutes of Health, 2015Scientists have added to the list of inherited genetic mutations known to increase th

Updated on: July 08,2024

Long-term study reveals more genetic mutations associated with aggressive prostate cancer

byInstitute of Cancer ResearchXenograft model of prostate cancer. Credit: National Institutes of Health, 2015Scientists have added to the list of inherited genetic mutations known to increase th

Updated on:July 08,2024

Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

by Elana GotkineFor patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative co

Updated on: December 28,2023

Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

by Elana GotkineFor patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a nonmyeloablative co

Updated on:December 28,2023

Breast cancer patients with government insurance at higher risk of death

by ECOG-ACRIN Cancer Research GroupSamilia Obeng-Gyasi, MD (The Ohio State University) is the lead author on an analysis of the insurance status of 9800 breast cancer patients and their clinical outco

Updated on: December 22,2023

Breast cancer patients with government insurance at higher risk of death

by ECOG-ACRIN Cancer Research GroupSamilia Obeng-Gyasi, MD (The Ohio State University) is the lead author on an analysis of the insurance status of 9800 breast cancer patients and their clinical outco

Updated on:December 22,2023

Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate

Updated on: December 26,2023

Unveiling the non-canonical functions of EZH2 in prostate cancer

by Impact Journals LLCProstate cancer cells. Credit: NIH Image GalleryA new editorial paper was published inOncotargettitled "Unveiling the non-canonical functions of EZH2 in prostate

Updated on:December 26,2023